Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy

A cutting edge therapy for future immuno-oncology is targeting a new series of inhibitory receptors (IRs): LAG-3, TIM-3, and TIGIT. Both immunogenomic analyses and diagnostic platforms to distinguish candidates and predict good responders to these IR-related agents are vital in clinical pathology. B...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamatsu, Kimiharu, Tanaka, Nobuyuki, Hakozaki, Kyohei, Takahashi, Ryohei, Teranishi, Yu, Murakami, Tetsushi, Kufukihara, Ryohei, Niwa, Naoya, Mikami, Shuji, Shinojima, Toshiaki, Sasaki, Takashi, Sato, Yusuke, Kume, Haruki, Ogawa, Seishi, Kakimi, Kazuhiro, Kamatani, Takashi, Miya, Fuyuki, Tsunoda, Tatsuhiko, Aimono, Eriko, Nishihara, Hiroshi, Sawada, Kazuaki, Imamura, Takeshi, Mizuno, Ryuichi, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452744/
https://www.ncbi.nlm.nih.gov/pubmed/34545095
http://dx.doi.org/10.1038/s41467-021-25865-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452744/
https://www.ncbi.nlm.nih.gov/pubmed/34545095
http://dx.doi.org/10.1038/s41467-021-25865-0

Ejemplares similares